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Abstract
Background: Persistent atrial fibrillation (AF) is difficult to treat. In the absence of class I or III
antiarrhythmic drugs sinus rhythm is maintained in only 30% of patients during the first year after
electrical cardioversion (ECV). One of the remodeling processes induced by AF is fibrosis, which
relates to inducibility and maintenance of AF. The renin-angiotensin system may play a important
role in this. The aim of this study was to investigate the role of angiotensin-converting enzyme
(ACE) inhibitor use on efficacy of ECV, and occurrence of subacute recurrences.
Methods: One hundred-seven consecutive patients with persistent AF underwent ECV. In twenty-
eight (26%) patients ACE inhibitors had been started before initiation of the present episode of AF
('pre-treated' patients).
Results: ECV was successful in 96% of patients who were on ACE inhibitors before start of the
present episode of AF compared to 80% of the patients not pre-treated (p = 0.04). After 1 month
of follow-up 49% of the pre-treated patients and 50% of those not pre-treated with ACE inhibition
were still in sinus rhythm (p=ns). Multivariate analysis showed that pre-treatment with ACE
inhibitors and a smaller left atrial size were independent predictors of successful ECV (OR = 5.8,
C.I. 1.3–26.1, and OR = 5.6, C.I. 1.2–25.3, respectively).
Conclusions: Pre-treatment with ACE inhibitors may improve acute success of ECV but does not
prevend AF recurrences.
Background
Persistent atrial fibrillation (AF) is difficult to treat. In the
absence of class I or III antiarrhythmic drugs sinus rhythm
is maintained in only 30–50% of patients during the first
year after Direct Current electrical cardioversion
(ECV)[1,2]. Furthermore, even following an aggressive
approach with repeated ECVs and use of prophylactic
drugs, arrhythmia-free outcome is still poor: only 39% of
patients maintain sinus rhythm during two years of fol-
low-up[1,2]. Notwithstanding the recent results of
AFFIRM and RACE showing no beneficial effect of rhythm
control over rate control a rhythm control strategy may be
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a tachycardiomyopathy[3]. In recent years research has
focused on the atrial remodeling processes that are
induced by AF itself and that trigger the arrhythmia to
become sustained: "AF begets AF"[4]. One of the remode-
ling processes induced by AF is fibrosis. Fibrosis causes
dispersion of conduction, which, in its turn is related to
inducibility of AF[5]. The renin-angiotensin system seems
to play an important role in the development of fibrosis
in heart failure. It was shown that pre-treatment with enal-
april may attenuate atrial fibrosis and conduction abnor-
malities in a canine model of heart failure, and the
occurrence of AF in patients with left ventricular dysfunc-
tion [5-7]. A recent experimental study showed that angi-
otensin II blockers may prevent electrical remodeling
when started before start of AF[8].
In the present study we report on the effects of ACE inhi-
bition on the outcome of ECV and the prevention of early
recurrences after ECV of persistent AF.
Methods
One hundred-seven consecutive patients with persistent
AF, defined as the presence of AF for at least 24 hours were
included in this study[9]. ECV was performed according
to a previously described step up protocol[10]. Successful
ECV was defined as the presence of sinus rhythm for at
least 4 hours after ECV. No difference was made between
unsuccessful ECV due to shock failure or due to an imme-
diate recurrence of AF (within 2 minutes after successful
ECV). ACE pre-treatment was defined as use of ACE inhib-
itors before onset of the current AF episode. Most patients
on ACE inhibitors used these drugs for hypertension or
congestive heart failure. To make sure that all patients
were not completely remodeled at the very moment of
start of the current episode of AF (and thereby verifying
the fact that they were treated with ACE inhibitors before
the process of electrical remodeling started), only patients
with at least 1 month sinus rhythm before the current epi-
sode of AF were included in this study. Duration of AF was
determined as precisely as possible by previous electrocar-
diograms, 24-hours Holter registrations, and by the
Table 1: Baseline characteristics
All Successful ECV Unsuccessful ECV P
N = 107 N = 90 N = 17
Duration in days, median (range)
current episode 115(71–175) 113 (61–175) 126 (81–189) ns
total AF duration 144 (95–232) 142 (86–213) 160 (102–340) Ns
Number of previous ECVs, N(range) 1 (0–5) 1 (0–5) 1(0–3) Ns
Underlying heart disease * (%)
Left ventricular dysfunction 21% 25% 0% 0.02
Hypertension 30% 32% 17% ns
Valve disease 19% 19% 22% ns
Coronary artery disease 22% 21% 28% ns
Lone AF 16% 16% 15% ns
Echocardiography (mm ± SD)
LA parasternal long axis 47 ± 8 47 ± 9 47 ± 8 ns
LA 4 chamber view long axis 67 ± 9 67 ± 10 67 ± 6 ns
LA 4 chamber view short axis 46 ± 8 46 ± 9 43 ± 5 ns
RA 4 chamber view long axis 62 ± 8 62 ± 8 63 ± 7 ns
LVEDD 50 ± 8 50 ± 8 50 ± 7 ns
LVESD 35 ± 10 35 ± 10 33 ± 9 ns
Medication
Beta blocker 49% 50% 48% ns
Calcium channel blocker 36% 36% 37% ns
Digoxin 47% 46% 49% ns
ACE pretreatment 26% 30% 6% 0.04
Diuretics 31% 31% 29% ns
Angiotensin receptor blocker 1% 1% 0% ns
* more then 1 entity per patient
AF = atrial fibrillation, ECV = electrical cardioversion, LA = left atrium, RA = right atrium, LVEDD = left ventricular end diastolic diameter, LVESD 
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antiarrhythmic drugs neither at the moment of ECV nor
during follow-up.
Statistical analysis
Quantitative variables were compared between groups
using a two-tailed t-test for normally distributed variables
or a Wilcoxon two-sample test for skewed distributed var-
iables. For qualitative variables (categorical or ordered),
group differences were evaluated using a Fisher's exact test
or a Chi-square test. Accordingly, baseline characteristics
are given in mean ± SD, median and range (min-max) or
percentages.
To determine the predictive factors for successful ECV, an
univariate logistic regression analysis was performed
using the relevant baseline predictors. Variables with a p-
value < 0.20 were selected for the multiple logistic regres-
sion analysis to derive a model with statistically signifi-
cant predictors, by using a backward selection method. All
p-values are two-sided and a p-value of < 0.05 was consid-
ered statistically significant. SAS version 6.12 (Cary, NC)
was used for all statistical evaluations.
Results
Baseline characteristics are listed in table 1. Twenty-eight
patients (26%) were treated with ACE inhibitors before
start of the current episode of AF (pre-treated patients). In
the latter group, ECV was successful in 96% while in the
group of patients not pre-treated with ACE inhibitors
before start of the current AF episode only 80% had a suc-
cessful ECV (p = 0.04).
In general, patients treated with ACE inhibitors before
start of the current episode of AF had more evidence for
heart disease than those who were not pre-treated. Preva-
lence of hypertension (46% versus 24%, respectively, p =
0.03), and left ventricular dysfunction (40% versus 14%,
respectively, p = 0.01) was significantly higher in the pre-
treated group in comparison to those who were not pre-
treated with ACE inhibitors. (Table 2) Furthermore, there
was a trend towards a higher prevalence of coronary artery
disease in the pre-treated group compared to the not pre-
treated group (36% versus 18%, respectively p = 0.07).
An additional 21 patients received ACE inhibitors after
start of the current episode of AF because of either
Table 2: Baseline characteristics divided in ACE pre-treatment and no ACE pre-treatment.
No ACE pre-treatment ACE-pre-treatment P
N = 79 N = 28
Duration in days, median (range)
current episode 121 (74–178) 96 (59–135) ns
total AF duration 161 (105–247) 117 (63–160) ns
Number of previous ECVs, N(range) 1 (0–5) 1(0–3) ns
Underlying heart disease * (%)
Left ventricular dysfunction 14% 40% 0.01
Hypertension 24% 46% 0.03
Valve disease 19% 21% ns
Coronary artery disease 18% 36% 0.07
Lone AF 17% 14% ns
Echocardiography (mm ± SD)
LA parasternal long axis 46 ± 7 50 ± 10 0.03
LA 4 chamber view long axis 66 ± 9 67 ± 12 ns
LA 4 chamber view short axis 45 ± 8 49 ± 10 ns
RA 4 chamber view long axis 61 ± 8 64 ± 7 ns
LVEDD 49 ± 7 54 ± 8 0.01
LVESD 34 ± 9 38 ± 12 ns
Medication
Beta blocker 51% 47% ns
Calcium channel blocker 35% 39% ns
Digoxin 45% 51% ns
Diuretics 29% 34% ns
Angiotensin receptor blocker 1% 0% ns
* more then 1 entity per patient
AF = atrial fibrillation, ECV = electrical cardioversion, LA = left atrium, RA = right atrium, LVEDD = left ventricular end diastolic diameter, LVESD 
= left ventricular end systolic diameterPage 3 of 6
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function newly documented with echocardiography. Suc-
cess of ECV in these patients was comparable to patients
who were not treated with ACE inhibitors at all (80% and
82%, respectively). Use of beta adrenergic receptor block-
ers, calcium channel blockers or digoxin, started before
the present episode of AF or not, did not influence success
of ECV.
After 1 month of follow-up 49% of the pre-treated
patients compared to 50% of those who were not pre-
treated with ACE inhibition were still in sinus rhythm
(Table 3, Figure 1).
Multivariate analysis showed that pre-treatment with ACE
inhibitors and a smaller left atrial size were independent
predictors of successful ECV (OR = 5.8, C.I. 1.3–26.1 and
OR = 5.6, C.I. 1.2–25.3, respectively).
Discussion
Main results
This post-hoc retrospective analysis shows that use of ACE
inhibitors before the onset of AF enhances acute ECV out-
come but it does not improve maintenance of sinus
rhythm. Furthermore, when ACE inhibitiors are instituted
later, i.e. after the start of AF, it does no longer improve
success of ECV.
Effect of ACE-inhibition on structural remodeling
ACE inhibitors reduce the incidence of AF in patients with
left ventricular dysfunction[7,6]. This may be related to
the protective effects of ACE inhibitors, which help to
maintain atrial integrity and attenuate fibrosis[5]. In the
present study pre-treatment with an oweveHowACE
inhibitor (i.e. use of ACE inhibitors before onset of the
arrhythmia) improved acute outcome of ECV. In view of
the above this suggests that ACE inhibitors may prevent or
diminish AF induced structural remodeling. These clinical
findings are compatible with experimental findings show-
ing that ACE-inhibition could attenuate heart failure
induced atrial functional remodeling and fibrosis in
dogs[11]. In atrial tissue from AF patients an ACE-depend-
ent increase of activated extracellular signal-regulated
kinase (Erk) type 1 and 2 was found, which may contrib-
ute to the development of atrial fibrosis during AF[12].
Effect of ACE-inhibition on electrical remodeling
In 1995 it was shown that AF induces several electrophys-
iological changes, called electrical remodeling[4]. Experi-
mental data show that ACE inhibition prevents short-term
(< 2 hours) tachycardia-induced atrial electrical remode-
ling[8,13]. However, enalapril could not attenuate or
prevent the long-term (7 days) effects of tachycardia on
remodeling[8]. Several studies have investigated the role
of calcium channel blockers on electrical remodeling. In
these studies it was also shown that although there was a
short-term prevention of electrical remodeling, calcium
channel blockers did not have a long-term protective
effect on electrical remodeling [14-16].
Table 3
All No ACE-pretreatment ACE-pretreatment P
Successful ECV (%) 84% 80% 96% 0.04
SR at 1 month follow-up (%) 50% 50% 49% ns
ECV = electrical cardioversion, SR = sinus rhythm
Effect of pretreatment with ACE-inhibitors before start of AFFigure 1
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Madrid et al. investigated the role of the angiotensin II
type 1 receptor antagonist irbesartan in amiodarone
treated patients[17]. Persistent AF patients were rand-
omized to either treatment with amiodarone alone or
treatment with amiodarone in combination with irbe-
sartan. Drug treatment was started at least 3 weeks before
cardioversion but after the start of AF. No differences were
found in electrical cardioversion outcome between the
two treatment groups which is in contrast to the present
study. This may relate to the fact that all patients were in
AF at the very moment of start of irbesartan. Two months
after cardioversion it appeared that patients treated with
irbesartan and amiodarone had a significantly lower AF
recurrence rate compared to amiodarone alone treated
patients, 15% versus 37%, respectively (p = 0.007). This
difference was maintained during a median follow-up of
254 days. According to their figure 2, the benefit of irbe-
sartan (in combination with amiodarone) was mainly
achieved by reduction of recurrences after the first two
weeks after cardioversion. An earlier study on the role of
ACE inhibitors in patients with heart failure and AF
showed a trend towards more patients maintaining sinus
rhythm after ECV when instituted on lisinopril in compar-
ison to patients not treated with lisinopril[18]. In the
present study no difference in recurrence rate could be
found between patients with and without ACE-pretreat-
ment.
Limitations of the study
This was a non-randomized and post-hoc analysis. This
implies that all findings can only be used to generate
hypotheses. However, this is the first clinical study show-
ing that ACE-inhibition initiated before start of AF
enhances direct ECV outcome.
Only a very small amount of patients was on angiotensin
receptor blockers. Whether the effect of pretreatment with
angiotensin receptor blockers on cardioversion outcome
would be the same as the effect of pretreatment with ACE
inhibitors could not be investigated in this study. How-
ever, in this context the results of the study of Madrid et al.
are encouraging [17].
Conclusions
Pretreatment with ACE-inhibitors significantly improves
acute outcome of ECV when initiated before the onset of
AF but it does not lead to better maintenance of sinus
rhythm. When ACE inhibitiors are, however, instituted
later, i.e. after the start of AF, it does no longer improve
success of ECV.
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